Jiangsu Recbio Technology Co., Ltd. (HKG:2179)
Hong Kong
· Delayed Price · Currency is HKD 4.290
0.00 (0.00%)
At close: Mar 10, 2026
Jiangsu Recbio Technology Revenue
Jiangsu Recbio Technology had revenue of 19.73M CNY in the half year ending June 30, 2025, with 329.17% growth. This brings the company's revenue in the last twelve months to 29.11M, down -32.92% year-over-year. In the year 2024, Jiangsu Recbio Technology had annual revenue of 27.01M, down -11.10%.
Revenue (ttm)
29.11M CNY
Revenue Growth
-32.92%
P/S Ratio
82.94
Revenue / Employee
57.42K CNY
Employees
507
Market Cap
2.65B HKD
Revenue Chart
* This company reports financials in CNY.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Antengene Corporation | 92.43M |
| SinoMab BioScience | 6.28M |
| Clover Biopharmaceuticals | 56.73M |
| BioDlink International Company | 1.17B |
| Frontage Holdings | 1.99B |
| Medtide | 546.29M |
| Hangzhou Jiuyuan Genetic Biopharmaceutical | 1.43B |
| AIM Vaccine | 1.38B |